TITUSVILLE, N.J., May 11, 2026
Johnson & Johnson announced the presentation of 18 new and encore abstracts highlighting the company’s expanding leadership in neuropsychiatry research and development at the upcoming American Psychiatric Association (APA) Annual Meeting in San Francisco and the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami. The presentations will feature new clinical and post-hoc analyses across the company’s neuroscience portfolio, including schizophrenia, major depressive disorder (MDD), treatment-resistant depression (TRD), insomnia-associated depression, and long-acting injectable therapies. Key programs highlighted include CAPLYTA® (lumateperone), seltorexant, and SPRAVATO® (esketamine) nasal spray, with new findings focused on relapse prevention, remission outcomes, cognitive performance, metabolic health, and patient-centered treatment approaches. Company executives stated that the data reinforce Johnson & Johnson’s commitment to advancing therapies targeting persistent and difficult-to-treat neuropsychiatric symptoms that continue to affect millions of patients globally.
CAPLYTA Data Highlights Long-Term Schizophrenia Relapse Prevention
One of the company’s major presentations at the APA Annual Meeting will feature long-term Phase 3 findings evaluating CAPLYTA® (lumateperone) for the prevention of relapse in schizophrenia patients. According to Johnson & Johnson, the oral presentation will examine both safety and efficacy outcomes associated with sustained treatment, an area of growing importance in schizophrenia management where relapse prevention remains a major unmet clinical need. Additional poster presentations scheduled for the ASCP Annual Meeting will present new analyses from pivotal Phase 3 studies evaluating CAPLYTA as an adjunctive treatment for major depressive disorder.
These analyses include remission outcomes across multiple patient subgroups and comparisons versus placebo treatment. The company emphasized that these findings may help clinicians better understand which patient populations could potentially benefit most from the therapy. Johnson & Johnson noted that improving remission rates and long-term symptom control remains central to advancing neuropsychiatric care, particularly in patients who continue experiencing residual symptoms despite existing standard therapies.
Seltorexant Studies Explore Depression and Insomnia Outcomes
Advertisement
Johnson & Johnson will also present updated analyses from Phase 3 studies evaluating seltorexant, an investigational therapy being studied as an adjunctive treatment for adults with major depressive disorder accompanied by insomnia symptoms. The company stated that oral presentations at ASCP 2026 will focus on efficacy findings related to symptom improvement in this patient population, while additional poster presentations will examine cognitive performance outcomes and metabolic effects observed during treatment.
Insomnia symptoms remain highly prevalent among patients with major depressive disorder and are often associated with increased disease burden, impaired functioning, and reduced treatment response. Johnson & Johnson believes the emerging seltorexant data further support the importance of addressing both mood and sleep-related symptoms simultaneously in depressive disorders. Researchers will also present post-hoc analyses exploring metabolic outcomes in treated adults, contributing to broader discussions around the long-term safety and tolerability profile of investigational neuropsychiatric therapies.
Expanded Neuropsychiatry Portfolio Demonstrates Broad Pipeline Strength
Beyond CAPLYTA and seltorexant, Johnson & Johnson will also showcase new analyses involving SPRAVATO® (esketamine) CIII nasal spray, specifically examining predictors of relapse among treatment-resistant depression patients who previously achieved response or remission in the Phase 3 SUSTAIN-1 long-term study. Additional sessions will focus on long-acting injectable (LAI) treatment strategies for schizophrenia, including consensus recommendations designed to help healthcare providers improve patient and caregiver engagement when discussing LAI treatment options. Company leadership stated that the breadth of data presented across APA and ASCP reflects Johnson & Johnson’s broader strategy of advancing neuroscience innovation across multiple psychiatric disorders with high unmet need.
Executives emphasized that many patients continue experiencing persistent cognitive, emotional, and functional impairments despite currently available treatments, reinforcing the need for more targeted and durable therapeutic approaches. Through ongoing research across schizophrenia, depression, and related neuropsychiatric conditions, the company aims to expand treatment options capable of delivering sustained symptom control, improved quality of life, and potentially higher remission rates for patients facing chronic mental health disorders.
Source: Johnson & Johnson press release
